Amneal Pharmaceuticals, Inc. (AMRX) Income Tax Expense (Benefit) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Amneal Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2017 to 2024.
  • Amneal Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $6.16 M, a 822% increase year-over-year.
  • Amneal Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending March 31, 2024 was $13.9 M, a 29.2% increase year-over-year.
  • Amneal Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $8.45 M, a 26.9% increase from 2022.
  • Amneal Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $6.66 M, a 40.5% decline from 2021.
  • Amneal Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $11.2 M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $13.9 M $6.16 M +$5.49 M +822% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $8.45 M $9.88 M +$11.7 M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 -$3.23 M -$2.08 M -$6.65 M -145% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $3.42 M -$23 K -$7.37 M -100% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $10.8 M $668 K +$4.13 M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $6.66 M -$1.8 M -$5.94 M -143% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $12.6 M $4.57 M +$521 K +12.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $12.1 M $7.35 M +$4.7 M +178% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $7.38 M -$3.46 M -$3.82 M -1064% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $11.2 M $4.14 M +$2.66 M +179% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $8.54 M $4.05 M +$3.91 M +2712% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $4.64 M $2.65 M +$462 K +21.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $4.17 M $359 K +$109 M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$104 M $1.49 M -$6.31 M -80.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-03
Q3 2020 -$98.1 M $144 K -$390 M -100% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $291 M $2.19 M +$7.89 M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $284 M -$108 M -$99.7 M -1183% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $383 M $7.79 M +$2.27 M +41.1% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $381 M $390 M +$385 M +7527% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$3.5 M -$5.7 M +$6.72 M +54.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$10.2 M -$8.43 M -$8.79 M -2415% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$1.42 M $5.52 M +$5.52 M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$6.94 M $5.11 M +$5.85 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$12.8 M -$12.4 M -$14.3 M -770% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $1.48 M $364 K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $0 Oct 4, 2017 Dec 31, 2017 10-K 2018-03-09
Q3 2017 -$738 K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $1.85 M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.